title: Prognostic factors in angiosarcoma: a multivariate analysis of 55 cases.
abstract: Data for prognostic factors in angiosarcoma (AS) are limited, prompting a large-scale study of AS with multivariate analysis. To analyze prognostic factors in angiosarcoma (AS), clinical and histologic findings in 55 patients collected from hospitals in Japan were reviewed. Prognostic factors were evaluated by univariate and multivariate Cox's proportional hazards models. The study involved 32 males and 23 females, ages 18-93 (median, 69) years. The primary sites of tumors included head and neck (32 cases), trunk (10), extremities (3), spleen (3), breast (3), and other (4). The overall 2-year survival rate was 21%. Univariate analysis of clinical factors including age, sex, size and depth of tumor, tumor-related symptoms, interval between onset of symptoms and admission, surgical procedures, adjuvant chemotherapy, and adjuvant radiotherapy showed that age, tumor size, and mode of treatment were significant for survival. Histologic factors analyzed were mitotic counts, cellularity, cellular pleomorphism, extent of necrosis, vascular differentiation, and nonspecific diagnosis. Only mitotic counts were significant for prognosis. Multivariate analysis on these four factors revealed that tumor size, mode of treatment, and mitotic counts were independent prognostic factors.
authors.affiliation: Department of Pathology, Osaka University School of Medicine, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Naka
authors.forename: M
authors.initials: M
authors.lastname: Ohsawa
authors.forename: Y
authors.initials: Y
authors.lastname: Tomita
authors.forename: H
authors.initials: H
authors.lastname: Kanno
authors.forename: A
authors.initials: A
authors.lastname: Uchida
authors.forename: A
authors.initials: A
authors.lastname: Myoui
authors.forename: K
authors.initials: K
authors.lastname: Aozasa
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D005121:Extremities / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000473:pathology / Q000601:surgery; D006394:Hemangiosarcoma / Q000098:blood supply / Q000473:pathology / Q000601:surgery*; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D008938:Mitosis; D015999:Multivariate Analysis; D009336:Necrosis; D010343:Patient Admission; D011379:Prognosis; D016016:Proportional Hazards Models; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D012737:Sex Factors; D013160:Splenic Neoplasms / Q000473:pathology / Q000601:surgery; D015996:Survival Rate; D013899:Thoracic Neoplasms / Q000473:pathology / Q000601:surgery; D016896:Treatment Outcome